Ulotaront (original) (raw)

Property Value
dbo:abstract Ulotaront (INN; developmental codes SEP-363856, SEP-856) is an investigational antipsychotic that is undergoing clinical trials for the treatment of schizophrenia and Parkinson's disease psychosis. The medication was discovered in collaboration between PsychoGenics Inc. and Sunovion Pharmaceuticals using PsychoGenics' behavior and AI-based phenotypic drug discovery platform, SmartCube. Ulotaront is in Phase III of clinical development. Research has shown that ulotaront results in a greater reduction from baseline in the PANSS total score than placebo. Treatment with ulotaront, as compared with placebo, was also associated with an improvement in sleep quality. Ulotaront was awarded a Breakthrough Therapy designation due to its increased efficacy and greatly reduced side effects compared to current treatments. (en) SEP-363856 eller SEP-856, är en antipsykotika som tillhandahålls av Sunovion. SEP-856 befinner sig på utredningstadiet än. (sv)
dbo:casNumber 1310426-33-5
dbo:fdaUniiCode 3K6270MG59
dbo:kegg D12474
dbo:pubchem 89532783
dbo:thumbnail wiki-commons:Special:FilePath/SEP-363856.svg?width=300
dbo:wikiPageExternalLink https://adisinsight.springer.com/drugs/800036955
dbo:wikiPageID 61101068 (xsd:integer)
dbo:wikiPageLength 10842 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID 1122158164 (xsd:integer)
dbo:wikiPageWikiLink dbr:Psychosis dbr:Schizophrenia dbr:Trace_amine-associated_receptor_1 dbr:Dopamine_receptor dbr:List_of_investigational_antipsychotics dbc:Amines dbc:Experimental_drugs dbr:Brain dbr:TAAR1_agonist dbr:Antipsychotic dbr:Lurasidone dbr:Clinical_trial dbr:Receptor_antagonist dbr:Positive_and_Negative_Syndrome_Scale dbr:Trace_amine-associated_receptor dbc:5-HT1A_agonists dbr:Agonist dbr:Akathisia dbr:5-HT1A_receptor dbc:Antipsychotics dbr:Food_and_Drug_Administration dbr:Breakthrough_therapy dbr:Parkinson's_disease dbc:TAAR1_agonists dbc:Thiophenes dbr:Dyspepsia dbr:Adverse_effect dbr:Dopamine dbr:Placebo dbr:Pharmacokinetic dbr:D2_receptor dbr:Raul_Gainetdinov dbr:Serotonin dbr:Mechanism_of_action dbr:Sleep dbr:Movement_disorder dbr:Sunovion dbr:Ralmitaront
dbp:c 9 (xsd:integer)
dbp:casNumber 1310426 (xsd:integer)
dbp:chemspiderid 61321168 (xsd:integer)
dbp:h 13 (xsd:integer)
dbp:iupacName 1 (xsd:integer)
dbp:kegg D12474 (en)
dbp:n 1 (xsd:integer)
dbp:o 1 (xsd:integer)
dbp:pubchem 89532783 (xsd:integer)
dbp:s 1 (xsd:integer)
dbp:smiles CNC[C@H]1C2=CC=CS2 (en)
dbp:stdinchi 1 (xsd:integer)
dbp:stdinchikey ABDDQTDRAHXHOC-QMMMGPOBSA-N (en)
dbp:synonyms SEP-363856; SEP-856 (en)
dbp:unii 3 (xsd:integer)
dbp:width 150 (xsd:integer)
dbp:wikiPageUsesTemplate dbt:Drugbox dbt:Reflist dbt:Short_description dbt:Abbrlink dbt:TAAR_ligands
dcterms:subject dbc:Amines dbc:Experimental_drugs dbc:5-HT1A_agonists dbc:Antipsychotics dbc:TAAR1_agonists dbc:Thiophenes
rdf:type owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment SEP-363856 eller SEP-856, är en antipsykotika som tillhandahålls av Sunovion. SEP-856 befinner sig på utredningstadiet än. (sv) Ulotaront (INN; developmental codes SEP-363856, SEP-856) is an investigational antipsychotic that is undergoing clinical trials for the treatment of schizophrenia and Parkinson's disease psychosis. The medication was discovered in collaboration between PsychoGenics Inc. and Sunovion Pharmaceuticals using PsychoGenics' behavior and AI-based phenotypic drug discovery platform, SmartCube. Ulotaront is in Phase III of clinical development. (en)
rdfs:label Ulotaront (en) SEP-363856 (sv)
owl:sameAs wikidata:Ulotaront dbpedia-sv:Ulotaront https://global.dbpedia.org/id/9T77f
prov:wasDerivedFrom wikipedia-en:Ulotaront?oldid=1122158164&ns=0
foaf:depiction wiki-commons:Special:FilePath/SEP-363856.svg
foaf:isPrimaryTopicOf wikipedia-en:Ulotaront
is dbo:wikiPageRedirects of dbr:SEP-363856 dbr:C9H13NOS dbr:SEP-856
is dbo:wikiPageWikiLink of dbr:List_of_investigational_antipsychotics dbr:SEP-363856 dbr:TAAR1 dbr:C9H13NOS dbr:Sunovion dbr:SEP-856
is foaf:primaryTopic of wikipedia-en:Ulotaront